An investigative synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum, was associated with greater improvements than placebo in patients with skin-predominant dermatomyositis — some of it ...

Single-cell analysis reveals fibroblast-mediated glycolysis drives systemic inflammation in dermatomyositis. Learn more about ...

Classic DM (CDM) presents with pathognomonic cutaneous findings and progressive, symmetric proximal muscle weakness. Cutaneous disease usually precedes the appearance of myositis by 3–6 months in ...

Dermatomyositis is a rare muscle disease that causes inflammation of the muscles, skin, and blood vessels. It may also affect other organs, such as the heart and lungs. Dermatomyositis belongs to a ...

NEW ORLEANS — A monoclonal antibody targeting interferon beta (IFN-beta) provided substantial reductions in the skin lesions associated with dermatomyositis in a double-blind, placebo-controlled phase ...

Dermatomyositis (DM) is a chronic autoimmune disease characterized by inflammatory myopathy and distinctive skin manifestations, significantly affecting patients' quality of life. Dazukibart, a novel ...

Please provide your email address to receive an email when new articles are posted on . Using the most recent EULAR/American College of Rheumatology criteria, researchers at the Mayo Clinic and the ...

Belonging to the same group of autoimmune diseases, both dermatomyositis and polymyositis cause muscle inflammation and weakness. But dermatomyositis also affects your skin and is more likely to ...